This message contains images. If you don't see images, click here to view.
Click
here to advertise in this news brief.
|
|
|
|
Microvascular damage in type 1 diabetic patients is reversed in the first year after simultaneous pancreas–kidney transplantation
American Journal of Transplantation (subscription required)
Simultaneous pancreas–kidney transplantation (SPK) is an advanced treatment option for type 1 diabetes mellitus (DM) patients with microvascular disease including nephropathy. Sidestreamdarkfield (SDF) imaging has emerged as a noninvasive tool to visualize the human microcirculation. This study assessed the effect of SPK in diabetic nephropathy (DN) patients on microvascular alterations using SDF and correlated this with markers for endothelial dysfunction.
|
|
Share this article:
    |
|
|
Continue the dialogue and pay it forward
AST
There is still time to Pay it Forward and encourage your colleagues to join AST, the home for all transplant professionals. Your recruitment efforts will help strengthen the transplantation community. When you Pay it Forward you’ll be entered to win an iPad with Retina display or AST bucks, and you'll be recognized at ATC, on the AST website and in the AST eNews. The deadline to submit applications is April 1, 2013. Learn more.
PRODUCT SHOWCASE
 |
|
Thompson Surgical Instruments, Inc. is the market leader in surgical retraction and the manufacturer of the original table mounted retractor. For more information, visit our website at thompsonsurgical.com or email us at info@thompsonsurgical.com.
|
|
AST Institutional Support Program
AST
Are you interested in receiving recognition and increased exposure for your transplant center? Does your center support the future of transplantation and value the educational, networking and research opportunities that the American Society of Transplantation (AST) provides to its members?
Does your center support AST's lobbying of the U.S. Congress and Federal Agencies to secure a more transplant provider friendly environment for patients and physicians?
If the answer to these questions is YES, please consider having your center participate in AST's Institutional Support Program.
With a charitable contribution of $3,000, your center will receive valuable benefits.
For more information or to make a contribution, click here.
All donations are tax-deductible.
Contact:
Liz Piegzik
AST Associate Meeting Manager
lpiegzik@myAST.com
Online Journal Club March 26, 2013: Hosted by Transplant Pharmacy COP
AST
AST members and non-members are invited to a free online journal club on Tuesday, March 26 at 3 p.m. ET. The article to be discussed is the "Effect of Corticosteroid Withdrawal on Tacrolimus and Mycophenolate Mofetil Exposure in a Randomized Multicenter Study" and author Dr. Fuad Shihab will participate in the discussion led by facilitator Lisa McDevitt-Potter, PharmD. Pre-registration is recommended to secure your place.
Live and On Demand Webinars - free for AST members
AST
Timely Topics in Transplantation webinar series
topics include new strategies in hepatitis management, DSA concerns and therapies, challenges of resistance — all available on demand 24/7.
Business of Transplantation webinar series
Second Wednesdays at 2 p.m. ET through June 2013 — topics include quality, finance and operations. Past webinars are available on demand 24/7.
Both webinar series are free for AST members and available for non-members for a fee.
Important ATC information
AST
Membership dues must be paid prior to April 1 to receive the member discounted registration rate to attend the 2013 ATC May 18-22 in Seattle. The member discounted rate will not be available if membership dues are submitted after April 1, and members who pay dues after April 1 will be required to register at the non-member rate. Additionally, members will not be able to pay membership dues on-site and then register on-site at the member discounted rate. Visit 2013.atcmeeting.org to register for the ATC. If you are uncertain whether your dues have been paid, or you have any other questions, please contact the AST office at info@myAST.org.
|
|
 |
|
Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. For more information about Astellas Pharma US, Inc., please visit our Web site at www.astellas.us
|
|
|
 |
|
LIFECODES is introducing its new HLA-SSO kits. The new kit includes a validated, high-performance enzyme for improved reliability and performance with the continued ease of no centrifugation or wash steps; providing accurate, clear and easy to interpret results.
|
|
|
 |
|
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. MORE
|
|
National Eye Donor Month: Donor family perspective
By Denise A. Valenti
 Rep. Alan Nunnelee, R-Miss., recently declared March to be the 2013 National Eye Donor Month to President Barack Obama. Nunnelee had suffered from the blinding disease keratoconus and was the recipient of two cornea donations that restored his vision. "I live every day with the knowledge that not only was my vision saved, it took tremendous strength and compassion on the part of two families to make it possible," Nunnelee said. The Eye Band Association of America has 97 member eye banks, and these members have designated the month to honor the donor families and increase the awareness of the need for eye donations.
Industry Pulse: Are you registered as an organ donor?
CDC confirms rabies death in organ transplant recipient
Centers for Disease Control and Prevention
The Centers for Disease Control and Prevention and Maryland Department of Health and Mental Hygiene have confirmed that a patient who recently died of rabies in Maryland contracted the infection through organ transplantation done more than a year ago. The patient was one of four people who had received an organ from the same donor. CDC laboratories tested tissue samples from the donor and from the recipient who died to confirm transmission of rabies through organ transplantation.
'Warmed liver' transplant first
BBC News
Surgeons in London have carried out the first 'warm liver' transplant using an organ which was 'kept alive' at body temperature in a machine. Usually donor livers are kept on ice, but many become damaged as a result. The patient, 62-year-old Ian Christie from Devon, is doing well after the operation at King's College Hospital. The technology was developed by scientists at Oxford University who hope it could increase the number of livers available for transplant.
Missed last week's issue? See which articles your colleagues read most.
Coronary events in patients undergoing orthotopic liver transplantation: Perioperative evaluation and management
Clinical Transplantation (subscription required)
Patients with advanced liver disease have a high prevalence of cardiac risk factors. The stress of liver transplant surgery predisposes these patients to major cardiac events, such as myocardial infarction or ventricular arrhythmias in addition to heart failure exacerbation. Thorough screening and optimal management of underlying cardiovascular pathology and cardiovascular risk factors should decrease the incidence of new cardiac events in liver transplant recipients.
The use of extracorporeal membranous oxygenation in donors after cardiac death
Current Opinion in Organ Transplantation (subscription required)
The use of ECMO in donors after cardio-circulatory death should be encouraged and further developed. Experimental work is in progress to better define the optimal conditions of the technique, which will help to limit or even repair the injuries, induced by warm ischaemia.
|
Transplant IV Biologics and Oral Immunosuppressives specializing in Desensitization and AMR Treatment and Prevention. MORE
|
|
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact James DeBois at 469-420-2618.
MORE
|
|
Quality assessment and performance improvement in transplantation: Hype or hope?
Current Opinion in Organ Transplantation (subscription required)
Healthcare reform and the national quality strategy is increasingly impacting transplant practice, as exemplified by quality assessment and performance improvement (QAPI) regulations for pretransplant and posttransplant care. Transplant providers consider not just patient comorbidities, donor quality and business constraints, but also regulatory mandates when deciding how to care for transplant candidates and recipients. This review describes transplant quality oversight agencies and regulations, and explores recent literature on the pros and cons of transplant QAPI.
Cytokine concentrations and regulatory T cells in living donor and deceased donor liver transplant recipients
Pediatric Transplantation (subscription required)
Outcomes of pediatric liver transplantation have constantly improved in the last decade. Living-related liver transplantation does not seem to improve long-term outcomes following liver transplantation, but few studies have evaluated immunological parameters of the alloimmune response after living vs. deceased donor organ transplantation. Living-related liver transplantation may have potentially beneficial immunological aspects, although long-term outcomes do not seem to be better in recipients of living donor organs than in recipients of deceased donor organs. Further studies are needed to compare immunological aspects of the two transplant procedures.
Old age alone should not prevent kidney transplants
Renal & Urology News
Elderly individuals should not be disqualified as kidney transplant recipients solely on the basis of age, researchers reported at the 28th annual congress of the European Association Urology.
Dr. Niall J. Dempster and colleagues in the Department of Surgery and Transplantation at Western Infirmary in Glasgow, U.K., reviewed data from 762 renal transplants performed from January 2001 to December 2010. They compared the rate of delayed graft function (DGF) and biopsy-proven acute rejection (BPAR), and other outcomes among elderly patients (older than 65 years) with those among younger patients.
Umbilical cord blood stem cell transplants may be an effective alternative to treat Hurler's syndrome
News-Medical.net
Transplants of blood-forming stem cells from umbilical cord blood may be an effective alternative to transplants of matched donor bone marrow stem cells to treat children with a rare, debilitating disease known as Hurler's syndrome (HS), according to results of a study published online today in Blood, the Journal of the American Society of Hematology (ASH).
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
Mobile version
